Trial Profile
A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections; Renal transplant rejection
- Focus Pharmacodynamics
- Sponsors Roche
- 25 Apr 2017 Status changed from recruiting to completed.
- 03 Mar 2014 Planned End Date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Feb 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.